Details

Autor(en) / Beteiligte

• Gupta, Shruti
• Coca, Steven G
• Chan, Lili
• Melamed, Michal L
• Brenner, Samantha K
• Hayek, Salim S
• Sutherland, Anne
• Puri, Sonika
• Srivastava, Anand
• Leonberg-Yoo, Amanda
• Shehata, Alexandre M
• Flythe, Jennifer E
• Rashidi, Arash
• Schenck, Edward J
• Goyal, Nitender
• Hedayati, S Susan
• Dy, Rajany
• Bansal, Anip
• Athavale, Ambarish
• Nguyen, H Bryant
• Vijayan, Anitha
• Charytan, David M
• Schulze, Carl E
• Joo, Min J
• Friedman, Allon N
• Zhang, Jingjing
• Sosa, Marie Anne
• Judd, Eric
• Velez, Juan Carlos Q
• Mallappallil, Mary
• Redfern, Roberta E
• Bansal, Amar D
• Neyra, Javier A
• Liu, Kathleen D
• Renaghan, Amanda D
• Christov, Marta
• Molnar, Miklos Z
• Sharma, Shreyak
• Kamal, Omer
• Boateng, Jeffery Owusu
• Short, Samuel A P
• Admon, Andrew J
• Sise, Meghan E
• Wang, Wei
• Parikh, Chirag R
• Leaf, David E

Titel

AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19

Ist Teil von

• Journal of the American Society of Nephrology, 2021-01, Vol.32 (1), p.161-176

Ort / Verlag

United States: American Society of Nephrology

Erscheinungsjahr

2021

Link zum Volltext

Quelle

EZB Free E-Journals

Beschreibungen/Notizen

• AKI is a common sequela of coronavirus disease 2019 (COVID-19). However, few studies have focused on AKI treated with RRT (AKI-RRT). We conducted a multicenter cohort study of 3099 critically ill adults with COVID-19 admitted to intensive care units (ICUs) at 67 hospitals across the United States. We used multivariable logistic regression to identify patient-and hospital-level risk factors for AKI-RRT and to examine risk factors for 28-day mortality among such patients. A total of 637 of 3099 patients (20.6%) developed AKI-RRT within 14 days of ICU admission, 350 of whom (54.9%) died within 28 days of ICU admission. Patient-level risk factors for AKI-RRT included CKD, men, non-White race, hypertension, diabetes mellitus, higher body mass index, higher d-dimer, and greater severity of hypoxemia on ICU admission. Predictors of 28-day mortality in patients with AKI-RRT were older age, severe oliguria, and admission to a hospital with fewer ICU beds or one with greater regional density of COVID-19. At the end of a median follow-up of 17 days (range, 1-123 days), 403 of the 637 patients (63.3%) with AKI-RRT had died, 216 (33.9%) were discharged, and 18 (2.8%) remained hospitalized. Of the 216 patients discharged, 73 (33.8%) remained RRT dependent at discharge, and 39 (18.1%) remained RRT dependent 60 days after ICU admission. AKI-RRT is common among critically ill patients with COVID-19 and is associated with a hospital mortality rate of >60%. Among those who survive to discharge, one in three still depends on RRT at discharge, and one in six remains RRT dependent 60 days after ICU admission.